Nomic Bio Debuts $50 Proteome with Absolute Quantification Through Launch of Omni 1000
Nomic Bio ("Nomic"), the Protein Profiling Company, today announced the launch of Omni 1000—a transformative high-plex solution now available through Nomic’s end-to-end service platform.
Omni 1000 brings together 1,000 rigorously chosen proteins, giving scientists proteome-wide breadth while retaining coverage of hallmark targets with proven utility across drug development and translational applications. The content, designed by combining expert biomarker curation with machine-learning on large annotated proteomic datasets, spans every Level 0 Reactome pathway, all major MeSH disease classes, and pharma-critical KEGG pathways.
Nomic Bio Debuts $50 Proteome with Absolute Quantification Through Launch of Omni 1000
Subscribe to Updates
Get the latest insights and updates delivered straight to your inbox weekly.
Nomic Bio ("Nomic"), the Protein Profiling Company, today announced the launch of Omni 1000—a transformative high-plex solution now available through Nomic’s end-to-end service platform.
Omni 1000 brings together 1,000 rigorously chosen proteins, giving scientists proteome-wide breadth while retaining coverage of hallmark targets with proven utility across drug development and translational applications. The content, designed by combining expert biomarker curation with machine-learning on large annotated proteomic datasets, spans every Level 0 Reactome pathway, all major MeSH disease classes, and pharma-critical KEGG pathways.
Nomic Bio ("Nomic"), the Protein Profiling Company, today announced the launch of Omni 1000—a transformative high-plex solution now available through Nomic’s end-to-end service platform.
Omni 1000 brings together 1,000 rigorously chosen proteins, giving scientists proteome-wide breadth while retaining coverage of hallmark targets with proven utility across drug development and translational applications. The content, designed by combining expert biomarker curation with machine-learning on large annotated proteomic datasets, spans every Level 0 Reactome pathway, all major MeSH disease classes, and pharma-critical KEGG pathways.
Nomic Bio Debuts $50 Proteome with Absolute Quantification Through Launch of Omni 1000
Nomic Bio ("Nomic"), the Protein Profiling Company, today announced the launch of Omni 1000—a transformative high-plex solution now available through Nomic’s end-to-end service platform.
Omni 1000 brings together 1,000 rigorously chosen proteins, giving scientists proteome-wide breadth while retaining coverage of hallmark targets with proven utility across drug development and translational applications. The content, designed by combining expert biomarker curation with machine-learning on large annotated proteomic datasets, spans every Level 0 Reactome pathway, all major MeSH disease classes, and pharma-critical KEGG pathways.
Access resource
Nomic Bio Debuts $50 Proteome with Absolute Quantification Through Launch of Omni 1000
Nomic Bio ("Nomic"), the Protein Profiling Company, today announced the launch of Omni 1000—a transformative high-plex solution now available through Nomic’s end-to-end service platform.
Omni 1000 brings together 1,000 rigorously chosen proteins, giving scientists proteome-wide breadth while retaining coverage of hallmark targets with proven utility across drug development and translational applications. The content, designed by combining expert biomarker curation with machine-learning on large annotated proteomic datasets, spans every Level 0 Reactome pathway, all major MeSH disease classes, and pharma-critical KEGG pathways.
Download resource
Get the latest insights and updates delivered straight to your inbox weekly.
Nomic Bio Debuts $50 Proteome with Absolute Quantification Through Launch of Omni 1000
Get the latest insights and updates delivered straight to your inbox weekly.
Nomic Bio ("Nomic"), the Protein Profiling Company, today announced the launch of Omni 1000—a transformative high-plex solution now available through Nomic’s end-to-end service platform.
Omni 1000 brings together 1,000 rigorously chosen proteins, giving scientists proteome-wide breadth while retaining coverage of hallmark targets with proven utility across drug development and translational applications. The content, designed by combining expert biomarker curation with machine-learning on large annotated proteomic datasets, spans every Level 0 Reactome pathway, all major MeSH disease classes, and pharma-critical KEGG pathways.